StoxAbbott India vs Ipca Laboratories: share price & financials comparison
NSE: ABBOTINDIA vs IPCALAB · Healthcare · as of 06 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Abbott India vs Ipca Laboratories at a glance
Abbott India (ABBOTINDIA) has a market capitalisation of ₹55,983 Cr, against ₹49,263 Cr for Ipca Laboratories (IPCALAB). Over the past year Ipca Laboratories has returned +50.5%, compared with -11.3% for Abbott India. On valuation, Abbott India trades at a lower P/E of 34.7 versus 35.1. Abbott India comes out ahead on valuation and profitability. Ipca Laboratories comes out ahead on growth, momentum and technicals. Across the scored metrics below, Abbott India leads on 4 and Ipca Laboratories on 8. On StoxGud's 10-point checklist, Abbott India scores 5/10 and Ipca Laboratories scores 9/10.
| Metric | Abbott India | Ipca Laboratories |
|---|---|---|
| Size | ||
| Market cap | ₹55,983 Cr | ₹49,263 Cr |
| Revenue (latest FY) | — | ₹9,646 Cr |
| Net profit (latest FY) | — | ₹1,141 Cr |
| Valuation | ||
| P/E | 34.7 | 35.1 |
| P/B | — | 5.68 |
| Dividend yield | — | 0.11% |
| Profitability | ||
| Return on equity | — | 16.2% |
| Net profit margin | 23.1% | 13.4% |
| Operating margin | 28.1% | 22.5% |
| Growth | ||
| Revenue growth (YoY) | +4.3% | +13.8% |
| Net profit growth (YoY) | +17.1% | +32.8% |
| Revenue CAGR (multi-year) | — | +12.2% |
| Financial health | ||
| Debt to equity | — | 0.07 |
| Momentum | ||
| 1-month return | +1.0% | +0.2% |
| 1-year return | -11.3% | +50.5% |
| 3-year CAGR | +4.2% | +25.4% |
| 5-year CAGR | +5.6% | +12.9% |
| 10-year CAGR | +18.8% | +21.0% |
| Distance from 52W high | -12.8% | -3.4% |
| Technicals | ||
| RSI (14) | 52 | 65 |
| Price vs 200-day avg | -1.0% | +15.1% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Abbott India | Ipca Laboratories |
|---|---|---|
| Price above 50-day average | ✓ | ✗ |
| Price above 200-day average | ✗ | ✓ |
| 50-day average above 200-day (uptrend) | ✗ | ✓ |
| RSI in healthy 40–70 zone | ✓ | ✓ |
| Positive 1-year return | ✗ | ✓ |
| Return on equity above 15% | ✗ | ✓ |
| Debt to equity below 1 | ✗ | ✓ |
| Revenue growing year on year | ✓ | ✓ |
| Net profit margin above 10% | ✓ | ✓ |
| P/E below industry median | ✓ | ✓ |
| Score | 5/10 | 9/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Abbott India or Ipca Laboratories?
Abbott India has a market cap of ₹55,983 Cr and Ipca Laboratories has a market cap of ₹49,263 Cr as of 06 Nov 2026.
Which has a lower P/E, Abbott India or Ipca Laboratories?
Abbott India has the lower P/E: Abbott India trades at 34.7 and Ipca Laboratories at 35.1.
Which gave better returns in the last year, Abbott India or Ipca Laboratories?
Ipca Laboratories did better: Abbott India returned -11.3% and Ipca Laboratories returned +50.5% over one year.
Is Abbott India or Ipca Laboratories a better buy?
StoxGud does not give buy or sell recommendations. On our rules-based checklist Abbott India scores 5/10 and Ipca Laboratories scores 9/10; compare valuation, profitability, growth and momentum above and consult a SEBI-registered adviser.